NITE - Nightstar Therapeutics: Keep Your Eyes Peeled For September Catalysts

Nightstar Therapeutics (NASDAQ:NITE) is a clinical-stage biotechnology company focused on the development of gene therapies for the treatment of rare inherited retinal diseases. While the company is still at least 2 to 3 years away from commercializing its lead product candidate, I could see the stock moving higher in September due to two catalyst events: Preliminary data for its Phase 1/2 trial and positive surprises at the R&D Day in New York.

Company Description

Nightstar Therapeutics is a preclinical biotechnology company based in London. It was founded in 2013 and raised almost USD